SCHEMBL3965173

SCHEMBL3965173

CC(C)C[C@H](N)C(=O)OC1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn4c3c2CC[C@@H]4C)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.69
KCNH2 Q12809 6/20 0.48
AADAT Q8N5Z0 2/20 0.47
KDM4E B2RXH2 8/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP1A2 P05177 1/20 0.47
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 3/20 0.46
ALB P02768 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
POLB P06746 3/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410375 1.00 LMNA (0.69) LMNAKCNH2AADATKDM4ESMN1; SMN2
SCHEMBL3965168 1.00 LMNA (0.69) LMNAKCNH2AADATKDM4ESMN1; SMN2
SCHEMBL3968764 0.94 LMNA (0.73) LMNAKCNH2AADATKDM4ESMN1; SMN2
SCHEMBL966483 0.94 LMNA (0.73) LMNAKCNH2AADATKDM4ESMN1; SMN2
SCHEMBL3965024 0.94 LMNA (0.73) LMNAKCNH2AADATKDM4ESMN1; SMN2
SCHEMBL3968769 0.94 LMNA (0.73) LMNAKCNH2AADATKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL967999 0.93 LMNA (0.72) LMNAKCNH2AADATKDM4ESMN1; SMN2
Hydrochloric Acid SCHEMBL3974708 0.92 LMNA (0.69) LMNAKCNH2AADATKDM4ESMN1; SMN2
Acetic Acid SCHEMBL3970333 0.92 LMNA (0.71) LMNAKCNH2AADATKDM4ESMN1; SMN2
Acetic Acid SCHEMBL3970329 0.92 LMNA (0.71) LMNAKCNH2AADATKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1175217-B8 (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS WOCKHARDT LTD (IN) 2009-03-18 EP claimed
EP-2030620-A1 (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents Wockhardt Limited (IN) 2009-03-04 EP claimed
US-20080108646-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED 2008-05-08 US claimed
US-6750224-B1 USED TO SYSTEMICALLY AND TOPICALLY TREAT BACTERIAL GRAM-POSITIVE, GRAM-NEGATIVE AND ANAEROBIC INFECTIONS, ESPECIALLY RESISTANT MYCOBACTERIAL INFECTIONS AND EMERGING NOSOCOMIAL PATHOGEN INFECTIONS WOCKHARDT LIMITED (IN) 2004-06-15 US claimed
US-20030207908-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED (IN) 2003-11-06 US claimed
EP-1175217-A2 (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS Wockhardt Limited (IN) 2002-01-30 EP claimed
WO-2000068229-A2 (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS WOCKHARDT LIMITED (IN) 2000-11-16 WO claimed
US-8507519-B2 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED (IN) 2013-08-13 US disclosed
EP-1175217-B8 (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS WOCKHARDT LTD (IN) 2009-03-18 EP disclosed
EP-2030620-A1 (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents Wockhardt Limited (IN) 2009-03-04 EP disclosed
US-20080108646-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED 2008-05-08 US disclosed
US-20080044466-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED 2008-02-21 US disclosed
US-7247642-B2 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED (IN) 2007-07-24 US disclosed
US-6750224-B1 USED TO SYSTEMICALLY AND TOPICALLY TREAT BACTERIAL GRAM-POSITIVE, GRAM-NEGATIVE AND ANAEROBIC INFECTIONS, ESPECIALLY RESISTANT MYCOBACTERIAL INFECTIONS AND EMERGING NOSOCOMIAL PATHOGEN INFECTIONS WOCKHARDT LIMITED (IN) 2004-06-15 US disclosed
US-20030207908-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment WOCKHARDT LIMITED (IN) 2003-11-06 US disclosed
EP-1175217-A2 (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS Wockhardt Limited (IN) 2002-01-30 EP disclosed
WO-2000068229-A2 (S)-BENZOQUINOLIZINE CARBOXYLIC ACIDS AND THEIR USE AS ANTIBACTERIAL AGENTS WOCKHARDT LIMITED (IN) 2000-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207908-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment RPS27L, HBZ, WIZ LMNA 3278/4885KCNH2 3073/4885AADAT 631/4885
US-20080108646-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment CRYZ, SQLE, SDHA LMNA 2066/4885KCNH2 1622/4885AADAT 631/4885
US-20080044466-A1 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment CRYZ, SQLE, SDHA LMNA 2066/4885KCNH2 1622/4885AADAT 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.